Are you Dr. Bar?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 21 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1959 NE Pacific St
Seattle, WA 98195Phone+1 206-520-5000Fax+1 206-598-6963
Summary
- Dr. Merav Bar, MD is an oncologist in Seattle, Washington. She is currently licensed to practice medicine in Washington, New Hampshire, and Pennsylvania. She is affiliated with UW Medicine/University of Washington Medical Center and Fred Hutch Cancer Center.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2004 - 2006- University of WashingtonResidency, Internal Medicine, 2000 - 2003
The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1997
Certifications & Licensure
NH State Medical License 2024 - 2024
WA State Medical License 2002 - 2022
PA State Medical License 2015 - 2016- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Clinical Trials
- Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Start of enrollment: 2002 Sep 01
- Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant Start of enrollment: 2012 Dec 01
- Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease Start of enrollment: 2012 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence.Francesco Mazziotta, Lauren E Martin, Daniel N Eagan, Merav Bar, Sinéad Kinsella
Medrxiv. 2024-12-16 - Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study.Albert Oriol, Roman Hájek, Ivan Spicka, Irwindeep Sandhu, Yael C Cohen
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-01 - 6 citationsHA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.Elizabeth F Krakow, Michelle Brault, Corinne Summers, Tanya M Cunningham, Melinda A Biernacki
Blood. 2024-09-05
